New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia

Cristina Alonso‐VegaJulio A. UrbinaSergi SanzMaría‐Jesús PinazoJimy PintoVirginia GonzalezGimena RojasLourdes OrtizWilson GarcíaDaniel Lozano2026-03-222026-03-22202110.1136/bmjopen-2021-052897https://doi.org/10.1136/bmjopen-2021-052897https://andeanlibrary.org/handle/123456789/43768Citaciones: 36NCT03981523.enMedicineClinical trialDiseaseChemotherapyChagas diseaseOpen labelEpidemiologyGerontologyInternal medicinePhysical therapyNew chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Boliviaarticle